Alaunos Therapeutics, Inc.

TCRT

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001107421

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $3.0M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	short runway, thin data, degenerate in... not computable: dilution, distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Apr 30, 2026 194 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$1.66 2026-11-09; market equity $4.2M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

We are a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. On March 2, 2026, we announced positive preclinical proof-of-concept data for ALN1003 from two separate studies using a standard diet-induced obesity (DIO) mouse model in male C57BL/6 mice maintained on a high-fat diet (60% of calories from fat).

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 8.4						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%			
one or more required annual facts are missing					
Accruals ratio	(45.7%)	(6.6%)	8.4	800	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 82.0					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(1,020.47)	(0.35)	100.0	745	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	2.45x	2.95x	64.0	826	2025-12-31
Growth and financing, sleeve percentile 99.5					
Revenue growth, three-year compound	(88.0%)	10.1%	99.8	411	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	(64.3%)	2.2%	99.3	694	2025-12-31
Net share issuance, one year	not computable	2.5%			
prior share count is 30 days earlier					

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 0.5 months
Thin data	5 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-11-09 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(67.4%)	(1.9%)	9
Distance from 52-week high	(61.7%)	(27.5%)	18
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(69.9%)	(1.0%)	10
Book value to price	0.15	0.27	34
Sales to price	0.00	0.29	4
Composite equity issuance, five years	57.4%	20.8%	66
Relative strength against the sector, log excess return	(1.29)	(0.19)	9

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$124,000
Operating cash flow, four quarters	-$2.7M
Months of runway	0.5
Days since last periodic filing	88 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$86,272

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$4.2M	2025-12-31	2026-03-31	10-K	26-134720
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$2.9M	2025-12-31	2026-03-31	10-K	26-134720
3	assets	us-gaap:Assets	$3.0M	2025-12-31	2026-03-31	10-K	26-134720
4	assets	us-gaap:Assets	$2.8M	2024-12-31	2026-03-31	10-K	26-134720
5	current assets	us-gaap:AssetsCurrent	$2.0M	2025-12-31	2026-03-31	10-K	26-134720
6	current liabilities	us-gaap:LiabilitiesCurrent	$813,000	2025-12-31	2026-03-31	10-K	26-134720
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$924.6M	2025-12-31	2026-03-31	10-K	26-134720
8	operating income	us-gaap:OperatingIncomeLoss	-$4.2M	2025-12-31	2026-03-31	10-K	26-134720
9	book equity	us-gaap:StockholdersEquity	$2.2M	2025-12-31	2026-03-31	10-K	26-134720
10	liabilities	us-gaap:Liabilities	$813,000	2025-12-31	2026-03-31	10-K	26-134720
11	operating income	us-gaap:OperatingIncomeLoss	-$34.3M	2023-12-31	2025-03-31	10-K	25-047758
12	interest expense	us-gaap:InterestExpense	$1.9M	2023-12-31	2024-04-01	10-K	24-038868
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$5,000	2025-12-31	2026-03-31	10-K	26-134720
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$10,000	2024-12-31	2026-03-31	10-K	26-134720
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$5,000	2023-12-31	2025-03-31	10-K	25-047758
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.9M	2022-12-31	2024-04-01	10-K	24-038868
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$98,000	2025-12-31	2026-03-31	10-K	26-134720
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$5.0M	2024-12-31	2026-03-31	10-K	26-134720
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2024-12-31	2026-03-31	10-K	26-134720
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$30.1M	2023-12-31	2025-03-31	10-K	25-047758
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$197,000	2023-12-31	2025-03-31	10-K	25-047758
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$29.2M	2022-12-31	2024-04-01	10-K	24-038868
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$216,000	2022-12-31	2024-04-01	10-K	24-038868
24	assets	us-gaap:Assets	$8.3M	2023-12-31	2025-03-31	10-K	25-047758
25	assets	us-gaap:Assets	$64.9M	2022-12-31	2024-04-01	10-K	24-038868
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	2,402,372	2026-04-30	2026-04-30	10-K/A	26-197838
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	2,378,253	2026-03-31	2026-03-31	10-K	26-134720

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.